GlassScriptPhysician profile
Tanya Maxwell
NPI 1023045135
$1,652.05
in general payments reported to CMS, 2019-2025
25 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.50 · 2022: $42.52 · 2023: $556 · 2024: $559 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.32 | 2023-2025 | |
| Novo Nordisk INC | $204.85 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $154.78 | 2023-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $153.48 | 2023-2025 | Mounjaro, Trulicity |
| Pfizer INC. | $134.51 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $89.04 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.60 | 2023-2025 | Trulance, Xifaxan |
| Glaxosmithkline, LLC. | $63.16 | 2023 | Shingrix, Arexvy |
| Shield Therapeutics INC | $60.46 | 2023-2025 | Accrufer |
| Astrazeneca Pharmaceuticals LP | $60.19 | 2022-2025 | Breztri, Lokelma, Airsupra |
| Dexcom, INC. | $51.83 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.72 | 2023-2025 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $45.96 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $38.91 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $38.86 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.88 | 2023-2025 | Cologuard Collection Kit |
| Verona Pharma, INC. | $22.60 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $22.28 | 2024 | Voquezna |
| Eisai INC. | $21.50 | 2021 | |
| Viatris Specialty LLC | $21.15 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $21.12 | 2024 | Auvelity |
| Corcept Therapeutics | $18.38 | 2025 | Korlym |
| Inspire Medical Systems, INC. | $15.87 | 2025 | Inspire |
| Astellas Pharma US INC | $13.55 | 2023 | Myrbetriq |
| Paratek Pharmaceuticals, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Maxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.